Associations of polypharmacy with cognitive impairment and functional status among older adults

Abstract

Aim: Polypharmacy is increasingly prevalent among older adults and has been suggested as a potential risk factor for adverse health outcomes, including cognitive impairment and functional decline. Therefore, this study aimed to investigate the associations of polypharmacy with cognitive impairment and functional status among community-dwelling older adults using nationally representative data from the 2023 Korean Elderly Survey.

Methods: A cross-sectional analysis was conducted using data from 9,898 community-dwelling older adults without a diagnosis of dementia. Polypharmacy was defined as the concurrent use of five or more physician-prescribed medications. Cognitive function was assessed using the Korean version of the Mini-Mental State Examination (K-MMSE), with cognitive impairment defined as a score ≤ 23. Functional status was evaluated using the Korean Activities of Daily Living (K-ADL) and Korean Instrumental Activities of Daily Living (K-IADL). Logistic regression was used to estimate odds ratios and 95% confidence intervals (CIs) for cognitive impairment, while multiple linear regression analyses examined associations with functional status. Models were sequentially adjusted for sociodemographic characteristics, health behaviors, and the number of chronic diseases.

Results: Polypharmacy was associated with increased odds of cognitive impairment in the crude model (OR = 1.70, 95% CI: 1.40–2.05); however, this association was attenuated and became non-significant after adjustment for sociodemographic and health-related factors. In contrast, polypharmacy remained independently associated with poorer functional status in fully adjusted models, showing higher K-ADL scores (B = 0.14, p = 0.007) and K-IADL scores (B = 0.43, p < 0.001).

Conclusions: Polypharmacy was independently associated with functional impairment but not with cognitive impairment after comprehensive adjustment, suggesting that functional decline may represent a more sensitive and immediate consequence of complex medication use in older adults. These findings underscore the need for comprehensive geriatric assessment approaches that integrate medication review with functional evaluation.

Keywords

Activities of Daily Living / cognitive impairment / functional status / polypharmacy / older adults

References

[1] Legg S. World Population Prospects 2024: Summary of Results. Melbourne: Interaction; 2024; 52: 27.

[2] Skou ST, Mair FS, Fortin M, Guthrie B, Nunes BP, Miranda JJ, et al. Multimorbidity. Nat Rev Dis Primers. 2022; 8: 48.

[3] Pazan F, Wehling M. Polypharmacy in older adults: a narrative review of definitions, epidemiology and consequences. Eur Geriatr Med. 2021; 12: 443-52.

[4] Jennings ELM, O’Mahony D, Gallagher PF. Medication-related quality of life (MRQoL) in ambulatory older adults with multi-morbidity and polypharmacy. Eur Geriatr Med. 2022; 13: 579-83.

[5] Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004; 57: 6-14.

[6] Sera LC, McPherson ML. Pharmacokinetics and pharmacodynamic changes associated with aging and implications for drug therapy. Clin Geriatr Med. 2012; 28: 273-86.

[7] Schmucker DL. Liver function and phase I drug metabolism in the elderly: a paradox. Drugs Aging. 2001; 18: 837-51.

[8] Gutiérrez-Valencia M, Izquierdo M, Cesari M, Casas-Herrero Á, Inzitari M, Martínez-Velilla N. The relationship between frailty and polypharmacy in older people: a systematic review. Br J Clin Pharmacol. 2018; 84: 1432-44.

[9] Al-Azayzih A, Al-Qerem W, Al-Azzam S, Alzoubi KH, Jirjees F, Al-Kubaisi K, et al. Medications Associated with Geriatric Syndromes and Prescribing Patterns: The Impact of Excessive Polypharmacy in Older Adult Patients. Ther Clin Risk Manag. 2024; 20: 741-8.

[10] Yu X, Qian Y, Zhang Y, Chen Y, Wang M. Association between polypharmacy and cognitive impairment in older adults: A systematic review and meta-analysis. Geriatr Nurs. 2024; 59: 330-7.

[11] Calderón-Larrañaga A, Vetrano DL, Ferrucci L, Mercer SW, Marengoni A, Onder G, et al. Multimorbidity and functional impairment-bidirectional interplay, synergistic effects and common pathways. J Intern Med. 2019; 285: 255-71.

[12] Pieper NT, Grossi CM, Chan WY, Loke YK, Savva GM, Haroulis C, et al. Anticholinergic drugs and incident dementia, mild cognitive impairment and cognitive decline: a meta-analysis. Age Ageing. 2020; 49: 939-47.

[13] Richardson K, Fox C, Maidment I, Steel N, Loke YK, Arthur A, et al. Anticholinergic drugs and risk of dementia: case-control study. BMJ. 2018; 361: k1315.

[14] Roy P, Ghosh D, Sanyal R, Madhu NR, Dey A. The Controversy Surrounding Drugs Against Neurodegenerative Disorders: Benefit or Harm? Neuroprot Eff Phytochem Brain Ageing. 2024. pp. 373-86.

[15] Akinyemi RO, Mukaetova-Ladinska EB, Attems J, Ihara M, Kalaria RN. Vascular risk factors and neurodegeneration in ageing related dementias: Alzheimer’s disease and vascular dementia. Curr Alzheimer Res. 2013; 10: 642-53.

[16] Chatterji S, Byles J, Cutler D, Seeman T, Verdes E. Health, functioning, and disability in older adults-present status and future implications. Lancet. 2015; 385: 563-75.

[17] Gianfredi V, Nucci D, Pennisi F, Maggi S, Veronese N, Soysal P. Aging, longevity, and healthy aging: the public health approach. Aging Clin Exp Res. 2025; 37: 125.

[18] Jyrkkä J, Enlund H, Lavikainen P, Sulkava R, Hartikainen S. Association of polypharmacy with nutritional status, functional ability and cognitive capacity over a three-year period in an elderly population. Pharmacoepidemiol Drug Saf. 2011; 20: 514-22.

[19] Shoair OA, Nyandege AN, Slattum PW. Medication-related dizziness in the older adult. Otolaryngol Clin North Am. 2011; 44: 455-71, x.

[20] Kang E, Kim H, Jeong C, Kim S, Lee S, Joo B, et al. National Survey of Older Koreans. Seoul: Korean Institute for Health and Social Affairs; 2023.

[21] Smith L, Letendre S, Erlandson KM, Ma Q, Ellis RJ, Farhadian SF. Polypharmacy in older adults with HIV infection: Effects on the brain. J Am Geriatr Soc. 2022; 70: 924-7.

[22] Oyarzun-Gonzalez XA, Taylor KC, Myers SR, Muldoon SB, Baumgartner RN. Cognitive decline and polypharmacy in an elderly population. J Am Geriatr Soc. 2015; 63: 397-9.

[23] Sheikh-Taha M, Asmar M. Polypharmacy and severe potential drug-drug interactions among older adults with cardiovascular disease in the United States. BMC Geriatr. 2021; 21: 233.

[24] Arnold SV, de Lemos JA, Zheng L, Rosenson RS, Ballantyne CM, Alam S, et al.; GOULD Investigators. Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study. Diabetes Obes Metab. 2023; 25: 1750-7.

[25] Rojas-Solé C, Pinilla-González V, Lillo-Moya J, González-Fernández T, Saso L, Rodrigo R. Integrated approach to reducing polypharmacy in older people: exploring the role of oxidative stress and antioxidant potential therapy. Redox Rep. 2024; 29: 2289740.

[26] Atuah KN, Hughes D, Pirmohamed M. Clinical pharmacology: special safety considerations in drug development and pharmacovigilance. Drug Saf. 2004; 27: 535-54.

[27] Rochon PA, Gurwitz JH. The prescribing cascade revisited. Lancet. 2017; 389: 1778-80.

[28] Peron EP, Gray SL, Hanlon JT. Medication use and functional status decline in older adults: a narrative review. Am J Geriatr Pharmacother. 2011; 9: 378-91.

[29] Stuck AE, Walthert JM, Nikolaus T, Büla CJ, Hohmann C, Beck JC. Risk factors for functional status decline in community-living elderly people: a systematic literature review. Soc Sci Med. 1999; 48: 445-69.

[30] Bierman AS, Tinetti ME. Precision medicine to precision care: managing multimorbidity. Lancet. 2016; 388: 2721-3.

[31] Allen LA, Thompson JS, Stehlik J. STRONG-HF Evidence for Proactive, Patient-Centered Prescribing. JAMA Cardiol. 2024; 9: 103-4.

[32] Brooksbank JA, Faulkenberg KD, Tang WHW, Martyn T. Novel Strategies to Improve Prescription of Guideline-Directed Medical Therapy in Heart Failure. Curr Treat Options Cardiovasc Med. 2023; 25: 93-110.

[33] Apóstolo J, Cooke R, Bobrowicz-Campos E, Santana S, Marcucci M, Cano A, et al. Effectiveness of interventions to prevent pre-frailty and frailty progression in older adults: a systematic review. JBI Database System Rev Implement Rep. 2018; 16: 140-232.